Evidence map›Paper›PMID 21777513›Full record

ReviewBMB reports2011

Evaluating the progenitor cells of ovarian cancer: analysis of current animal models.

Shelby M King, Joanna E Burdette

Abstract readReview
In one paragraph

Review in BMB reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Advantages of the avian model for human ovarian cancer.Molecular and clinical oncology · 2015
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Ovarian cancer stem cells: elusive targets for chemotherapy.Medical oncology (Northwood, London, England) · 2012
    Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shelby M KingDepartment of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 60607, USA.
Joanna E Burdette

Funding

Ovulation, inclusion cysts, and p53 mutations in a mouse model of ovarian cancerR03CA139492 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI BURDETTE, JOANNA E · 2009 to 2010
$157k
NCI NIH HHS CA139492NCI NIH HHS R03 CA139492
6 · The paper itself

Abstract

Serous ovarian cancer is one of the most lethal gynecological malignancies. Progress on effective diagnostics and therapeutics for this disease are hampered by ambiguity as to the cellular origins of this histotype of ovarian cancer, as well as limited suitable animal models to analyze early stages of disease. In this report, we will review current animal models with respect to the two proposed progenitor cells for serous ovarian cancer, the ovarian surface epithelium and the fallopian tube epithelium.

Indexed as

Evaluation Studies as TopicModels, AnimalAnimalsEpitheliumFemaleGenetic Predisposition to DiseaseHumansNeoplastic Stem CellsOvarian Neoplasms

Identifiers

PMID21777513
PMCPMC3677720

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.